A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene

ClinicalTrials.gov ID: NCT02141828

Public ClinicalTrials.gov record NCT02141828. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 18, 2026, 4:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Study identification

NCT ID: NCT02141828
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Epizyme, Inc.; Industry
Enrollment: 18 participants

Conditions and interventions

Conditions

Interventions

EPZ-5676 Drug

Drug

Eligibility (public fields only)

Age range: 3 Months to 18 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 30, 2014
Primary completion: Apr 30, 2016
Completion: May 31, 2016
Last update posted: Jun 17, 2023

2014 – 2016

United States locations

U.S. sites: 8
U.S. states: 7
U.S. cities: 8

Facility	City	State	ZIP	Site status
Childrens Hospital Los Angeles	Los Angeles	California	90027	—
University of California San Francisco Medical Center-Parnassus	San Francisco	California	94143	—
Children's Hospital Colorado	Aurora	Colorado	80045	—
Emory Children's Healthcare of Atlanta	Atlanta	Georgia	30322	—
Johns Hopkins University	Baltimore	Maryland	21287	—
Dana Farber Cancer Institute	Boston	Massachusetts	02215	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio	45229	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02141828, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 17, 2023 · Synced May 18, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02141828 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →